Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Orforglipron Availability, Amazon Pharmacy, and Dosing Considerations
The US Food and Drug Administration approval of orforglipron (Fondayo) in April 2026 may mark a pivotal shift in obesity care—particularly as the first oral GLP-1 option designed for flexible, real-world use. Within days, Eli Lilly and Company announced broad availability, including a same-day delivery partnership with Amazon Pharmacy, signaling a rapid move toward improved access following years of supply constraints affecting agents like tirzepatide.Watch on HCPLiveIn this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, and Natalie…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.